Phio Pharmaceuticals (PHIO) Competitors

$1.09 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.10 +0.00 (+0.46%)

As of 05/22/2026 07:40 PM Eastern

PHIO vs. ATYR, XLO, ESLA, GOSS, and MGX

Should you buy Phio Pharmaceuticals stock or one of its competitors? MarketBeat compares Phio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phio Pharmaceuticals include aTyr Pharma (ATYR), Xilio Therapeutics (XLO), Estrella Immunopharma (ESLA), Gossamer Bio (GOSS), and Metagenomi (MGX). These companies are all part of the "pharmaceutical products" industry.

How does Phio Pharmaceuticals compare to aTyr Pharma?

Phio Pharmaceuticals (NASDAQ:PHIO) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Phio Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Phio Pharmaceuticals' return on equity of -77.34% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
aTyr Pharma	N/A	-100.14%	-73.55%

Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,184.40%. aTyr Pharma has a consensus price target of $25.67, indicating a potential upside of 5,138.10%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Phio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Phio Pharmaceuticals has higher earnings, but lower revenue than aTyr Pharma. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
aTyr Pharma	$190K	252.87	-$74.12M	-$0.73	N/A

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, aTyr Pharma had 4 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 4 mentions for aTyr Pharma and 0 mentions for Phio Pharmaceuticals. aTyr Pharma's average media sentiment score of 0.50 beat Phio Pharmaceuticals' score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Neutral
aTyr Pharma	Positive

Summary

aTyr Pharma beats Phio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Xilio Therapeutics currently has a consensus target price of $28.00, suggesting a potential upside of 239.39%. Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,184.40%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Phio Pharmaceuticals' return on equity of -77.34% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Xilio Therapeutics' average media sentiment score of 1.00 beat Phio Pharmaceuticals' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Xilio Therapeutics	Positive
Phio Pharmaceuticals	Neutral

Xilio Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Phio Pharmaceuticals has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.13	-$35.04M	-$3.55	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

Summary

Phio Pharmaceuticals beats Xilio Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Estrella Immunopharma's average media sentiment score of 3.00 beat Phio Pharmaceuticals' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Estrella Immunopharma	Very Positive
Phio Pharmaceuticals	Neutral

Estrella Immunopharma presently has a consensus price target of $8.00, suggesting a potential upside of 589.66%. Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,184.40%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Estrella Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

Estrella Immunopharma's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Estrella Immunopharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Summary

Estrella Immunopharma and Phio Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Gossamer Bio?

Phio Pharmaceuticals (NASDAQ:PHIO) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Phio Pharmaceuticals has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Gossamer Bio	-324.82%	N/A	-96.10%

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 7.2% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Phio Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.15, suggesting that its stock price is 115% more volatile than the broader market.

Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,184.40%. Gossamer Bio has a consensus price target of $5.00, indicating a potential upside of 2,279.82%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Phio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Phio Pharmaceuticals has higher earnings, but lower revenue than Gossamer Bio. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Gossamer Bio	$48.47M	1.02	-$170.37M	-$0.79	N/A

In the previous week, Gossamer Bio had 21 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 21 mentions for Gossamer Bio and 0 mentions for Phio Pharmaceuticals. Gossamer Bio's average media sentiment score of 0.06 beat Phio Pharmaceuticals' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Neutral
Gossamer Bio	Neutral

Summary

Gossamer Bio beats Phio Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Metagenomi has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Phio Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Metagenomi currently has a consensus price target of $9.00, suggesting a potential upside of 566.67%. Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,184.40%. Given Phio Pharmaceuticals' higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals has lower revenue, but higher earnings than Metagenomi. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	2.02	-$87.87M	-$2.30	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

57.3% of Phio Pharmaceuticals shares are held by institutional investors. 17.8% of Metagenomi shares are held by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Metagenomi's average media sentiment score of 0.00 equaled Phio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
Phio Pharmaceuticals	Neutral

Summary

Metagenomi beats Phio Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHIO vs. The Competition

Export

Metric	Phio Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.66M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.79	17.79	21.00	25.66
Price / Sales	N/A	336.21	562.18	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	0.77	5.86	10.41	7.14
Net Income	-$8.70M	$74.99M	$3.57B	$335.98M
7 Day Performance	2.83%	3.11%	6.40%	4.11%
1 Month Performance	-8.40%	-3.05%	3.54%	2.52%
1 Year Performance	-37.71%	34.38%	34.14%	35.04%

Phio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHIO Phio Pharmaceuticals	2.673 of 5 stars	$1.09 flat	$14.00 +1,184.4%	-37.7%	$12.66M	N/A	N/A	10
ATYR aTyr Pharma	2.231 of 5 stars	$0.52 -0.9%	$25.67 +4,883.8%	-86.9%	$49.91M	$190K	N/A	53	Gap Up
XLO Xilio Therapeutics	3.3073 of 5 stars	$8.22 +0.8%	$28.00 +240.8%	-33.3%	$49.15M	$53.48M	N/A	70	Positive News
ESLA Estrella Immunopharma	3.3306 of 5 stars	$1.16 +3.1%	$8.00 +592.6%	+11.5%	$47.79M	N/A	N/A	N/A	Positive News
GOSS Gossamer Bio	2.7904 of 5 stars	$0.21 +6.9%	$5.00 +2,327.2%	-82.5%	$47.64M	$48.47M	N/A	180	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHIO) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. ATYR, XLO, ESLA, GOSS, and MGX

How does Phio Pharmaceuticals compare to aTyr Pharma?

Summary

How does Phio Pharmaceuticals compare to Xilio Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Estrella Immunopharma?

Summary

How does Phio Pharmaceuticals compare to Gossamer Bio?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. ATYR, XLO, ESLA, GOSS, and MGX

How does Phio Pharmaceuticals compare to aTyr Pharma?

Which has more volatility and risk, PHIO or ATYR?

Is PHIO or ATYR more profitable?

Do analysts recommend PHIO or ATYR?

Which has preferable earnings & valuation, PHIO or ATYR?

Do insiders and institutionals believe in PHIO or ATYR?

Does the media favor PHIO or ATYR?

Summary

How does Phio Pharmaceuticals compare to Xilio Therapeutics?

Do analysts prefer XLO or PHIO?

Is XLO or PHIO more profitable?

Do institutionals and insiders hold more shares of XLO or PHIO?

Does the media refer more to XLO or PHIO?

Which has more volatility and risk, XLO or PHIO?

Which has better earnings and valuation, XLO or PHIO?

Summary

How does Phio Pharmaceuticals compare to Estrella Immunopharma?

Do institutionals and insiders have more ownership in ESLA or PHIO?

Does the media refer more to ESLA or PHIO?

Do analysts recommend ESLA or PHIO?

Which has stronger valuation and earnings, ESLA or PHIO?

Is ESLA or PHIO more profitable?

Which has more risk and volatility, ESLA or PHIO?

Summary

How does Phio Pharmaceuticals compare to Gossamer Bio?

Is PHIO or GOSS more profitable?

Do insiders & institutionals believe in PHIO or GOSS?

Which has more risk and volatility, PHIO or GOSS?

Do analysts rate PHIO or GOSS?

Which has stronger earnings & valuation, PHIO or GOSS?

Does the media favor PHIO or GOSS?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Which has more volatility and risk, MGX or PHIO?

Is MGX or PHIO more profitable?

Do analysts rate MGX or PHIO?

Which has higher valuation and earnings, MGX or PHIO?

Do insiders & institutionals hold more shares of MGX or PHIO?

Does the media refer more to MGX or PHIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools